For the first time in many years, national leaders in the United States are carefully reconsidering how certain regulated substances are classified, with particular attention on plant-based wellness products. As more states adopt medical and adult-use programs, public conversation has shifted. Currently, 38 states support medical access, and 24 allow personal use. This growing state-level framework has encouraged discussion about modernizing national policy. As a result, federal scheduling is now under thoughtful review.
For decades, this plant has been placed in the strictest category under national law, originally based on limited research from the 1970s. Since then, medical programs, patient experiences, and emerging studies have questioned that classification. In 2023, health officials recommended moving it to a more appropriate regulatory category that recognizes medical potential. The proposal is still under consideration by federal agencies. This moment marks a significant turning point in policy evaluation.
Reclassifying the substance would not make it fully legal nationwide, but it could acknowledge its therapeutic use and reduce certain restrictions. Supporters say the change may help researchers, patients, and even small businesses that operate in states where it is already permitted. It may also help align national laws with state-level systems. However, many regulations—including those involving banking and transportation—would still require future action from lawmakers.
This review reflects shifting public attitudes and a growing interest in responsible access and scientific study. Surveys show that most Americans support medical availability, and many hope for clearer, consistent rules. While final decisions have not been made, the discussion alone is a milestone. It represents a careful effort to balance public health, patient needs, and economic opportunity. Whatever the result, this movement may shape healthcare and policy for generations to come.